Logo image of VOR

VOR BIOPHARMA INC (VOR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:VOR - US9290332074 - Common Stock

14.77 USD
+1.28 (+9.49%)
Last: 1/14/2026, 7:41:16 PM
14.65 USD
-0.12 (-0.81%)
Pre-Market: 1/15/2026, 8:10:47 AM
Fundamental Rating

1

Overall VOR gets a fundamental rating of 1 out of 10. We evaluated VOR against 528 industry peers in the Biotechnology industry. Both the profitability and financial health of VOR have multiple concerns. VOR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • VOR had negative earnings in the past year.
  • VOR had a negative operating cash flow in the past year.
  • VOR had negative earnings in each of the past 5 years.
  • VOR had a negative operating cash flow in each of the past 5 years.
VOR Yearly Net Income VS EBIT VS OCF VS FCFVOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of VOR (-1389.92%) is worse than 95.45% of its industry peers.
Industry RankSector Rank
ROA -1389.92%
ROE N/A
ROIC N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
VOR Yearly ROA, ROE, ROICVOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • VOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VOR Yearly Profit, Operating, Gross MarginsVOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, VOR has more shares outstanding
  • The number of shares outstanding for VOR has been increased compared to 5 years ago.
  • VOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VOR Yearly Shares OutstandingVOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
VOR Yearly Total Debt VS Total AssetsVOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -28.59, we must say that VOR is in the distress zone and has some risk of bankruptcy.
  • VOR's Altman-Z score of -28.59 is on the low side compared to the rest of the industry. VOR is outperformed by 86.36% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -28.59
ROIC/WACCN/A
WACCN/A
VOR Yearly LT Debt VS Equity VS FCFVOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • VOR has a Current Ratio of 9.16. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Current ratio value of 9.16, VOR is doing good in the industry, outperforming 79.36% of the companies in the same industry.
  • A Quick Ratio of 9.16 indicates that VOR has no problem at all paying its short term obligations.
  • VOR has a better Quick ratio (9.16) than 79.36% of its industry peers.
Industry RankSector Rank
Current Ratio 9.16
Quick Ratio 9.16
VOR Yearly Current Assets VS Current LiabilitesVOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

  • VOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -85.24%.
EPS 1Y (TTM)-85.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • VOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.61% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-225.99%
EPS Next 2Y34.04%
EPS Next 3Y22.42%
EPS Next 5Y14.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VOR Yearly Revenue VS EstimatesVOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
VOR Yearly EPS VS EstimatesVOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -100 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • VOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year VOR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VOR Price Earnings VS Forward Price EarningsVOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VOR Per share dataVOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -20 -40 -60 -80 -100

4.3 Compensation for Growth

  • VOR's earnings are expected to grow with 22.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.04%
EPS Next 3Y22.42%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for VOR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

VOR BIOPHARMA INC

NASDAQ:VOR (1/14/2026, 7:41:16 PM)

Premarket: 14.65 -0.12 (-0.81%)

14.77

+1.28 (+9.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-18
Inst Owners37.49%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner Change-167.03%
Market Cap323.61M
Revenue(TTM)N/A
Net Income(TTM)-2.45B
Analysts82
Price Target41.41 (180.37%)
Short Float %9.39%
Short Ratio1.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-197.99%
Min EPS beat(2)-394.6%
Max EPS beat(2)-1.38%
EPS beat(4)0
Avg EPS beat(4)-115.27%
Min EPS beat(4)-394.6%
Max EPS beat(4)-1.38%
EPS beat(8)3
Avg EPS beat(8)-56.4%
EPS beat(12)4
Avg EPS beat(12)-37.86%
EPS beat(16)6
Avg EPS beat(16)-27.88%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.5%
PT rev (3m)13.57%
EPS NQ rev (1m)51.64%
EPS NQ rev (3m)25.5%
EPS NY rev (1m)-469.34%
EPS NY rev (3m)-311.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-61.13
EYN/A
EPS(NY)-6.92
Fwd EYN/A
FCF(TTM)-6.6
FCFYN/A
OCF(TTM)-6.57
OCFYN/A
SpS0
BVpS-101.57
TBVpS-101.57
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1389.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.16
Quick Ratio 9.16
Altman-Z -28.59
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.83%
Cap/Depr(5y)265.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-85.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.38%
EPS Next Y-225.99%
EPS Next 2Y34.04%
EPS Next 3Y22.42%
EPS Next 5Y14.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-211.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-208.61%
EBIT Next 3Y-23.95%
EBIT Next 5YN/A
FCF growth 1Y-50.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.18%
OCF growth 3YN/A
OCF growth 5YN/A

VOR BIOPHARMA INC / VOR FAQ

What is the fundamental rating for VOR stock?

ChartMill assigns a fundamental rating of 1 / 10 to VOR.


What is the valuation status for VOR stock?

ChartMill assigns a valuation rating of 1 / 10 to VOR BIOPHARMA INC (VOR). This can be considered as Overvalued.


How profitable is VOR BIOPHARMA INC (VOR) stock?

VOR BIOPHARMA INC (VOR) has a profitability rating of 0 / 10.


What is the financial health of VOR BIOPHARMA INC (VOR) stock?

The financial health rating of VOR BIOPHARMA INC (VOR) is 3 / 10.


What is the earnings growth outlook for VOR BIOPHARMA INC?

The Earnings per Share (EPS) of VOR BIOPHARMA INC (VOR) is expected to decline by -225.99% in the next year.